Enregistrement :
38
de
50
(2021-05-17
à
2021-08-03)
Politique ou Programme
COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the re-opening of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
Canada’s engagement and leadership on programs and policies relating to mental health both domestic and international
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Agreement (NAFTA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies
Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas
Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products
Communiation to officials regarding the Regulatory Cooperation council.
Engagement on government’s Innovation Agenda as it relates to Health and Bio Sciences sector
Evolution of role and mandate of drug pricing regime in Canada
Food and Drug Act: Delays in product approvals and changes to existing products
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
Self-care – Regarding the development of policies and programs to support self-care, including tax incentives for self-care products that have an impact on health (for e.g. sunscreen, smoking cessation).
Smoking cessation – Regarding the development of federally funded programs or other policies to facilitate smoking cessation (for e.g. tobacco tax).
Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
Politique ou Programme, Règlement
Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drug Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products
Proposition législative, Projet de loi ou résolution
Changes to NAFTA to address United States-Mexico-Canada Agreement (USMCA) relevant for life sciences sector
Communication regarding the review by the Health Committee on regulation of e-cigarettes.
Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing plastic waste management programs.
Règlement
Communication to officials on labelling and product monographs.
Communication to officials regarding Look Alike Sound Alike Guidance communication.
Food and Drug Regulation: Nonprescription drugs labelling standards - Drug Products: Draft Guidance Document: Nonprescription Oral Pediatric Cough and Cold Labelling Standard,participated in Health Canada's consultation process
Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information
any regulatory changes that may emerge relating to the policy areas identified above including Health Canada Modernization efforts, Patented Medicine Prices Review Board (PMPRB), Treasury Board Initiative on international regulatory cooperation